AC
CRL icon

Apogem Capital’s Charles River Laboratories CRL Stock Holding History

Apogem Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,370
Closed -$466K – 23
2022
Q3 		$466K Buy
2,370
+235
+11% +$50.7K 0.46% 70
2022
Q2 		$457K Sell
2,135
-194
-8% -$47.4K 0.41% 80
2022
Q1 		$661K Buy
2,329
+1,165
+100% +$359K 0.45% 78
2021
Q4 		$439K Buy
+1,164
New +$452K 0.29% 108

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Apogem Capital's CRL Position: Q4 2022 in Review

Apogem Capital sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 2,370 shares — an estimated $466K sold.

Apogem Capital first reported a position in CRL in Q4 2021 and held it in 4 quarters. The position peaked at $661K in Q1 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Apogem Capital reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 2,370 Charles River Laboratories shares in Q4 2022, an estimated $466K.
  • Apogem Capital first reported a position in Charles River Laboratories in Q4 2021 and held it in 4 quarters.
  • Apogem Capital's Charles River Laboratories position peaked at $661K in Q1 2022.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.